Cargando…
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
Today, potential immunogenicity can be better evaluated during the drug development process, and we have rational approaches to manage the clinical consequences of immunogenicity. The focus of the scientific community should be on developing sensitive diagnostics that can predict immunogenicity-medi...
Autores principales: | Kuriakose, Anshu, Chirmule, Narendra, Nair, Pradip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942633/ https://www.ncbi.nlm.nih.gov/pubmed/27437405 http://dx.doi.org/10.1155/2016/1298473 |
Ejemplares similares
-
Posttranslational Modifications and the Immunogenicity of Biotherapeutics
por: Jefferis, Roy
Publicado: (2016) -
Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023) -
Posttranslational Modifications in Ferroptosis
por: Wei, Xiang, et al.
Publicado: (2020) -
Posttranslational Chemical Mutagenesis Methods to Insert Posttranslational Modifications into Recombinant Proteins
por: Harel, Omer, et al.
Publicado: (2022) -
S-Layer Glycoproteins and Flagellins: Reporters of Archaeal Posttranslational Modifications
por: Jarrell, Ken F., et al.
Publicado: (2010)